PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30959824-11 2019 The mechanism was primarily verified by the JAK2 inhibitor Ruxolitinib and the STAT3 inhibitor Stattic. ruxolitinib 59-70 Janus kinase 2 Mus musculus 44-48 30305729-10 2019 Importantly, the in vivo pro-tumorigenic effect of CA-MSC is abrogated by dual blockade with the JAK2 inhibitor ruxolitinib to a much greater extent than treatment with anti-IL6 or anti-LIF antibody alone. ruxolitinib 112-123 Janus kinase 2 Mus musculus 97-101 28854975-8 2017 Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level. ruxolitinib 60-71 Janus kinase 2 Mus musculus 44-48 30247637-16 2018 Ruxolitinib also inhibits JAK2, with decreased efficacy. ruxolitinib 0-11 Janus kinase 2 Mus musculus 26-30 29515770-4 2018 Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor, with activity against myeloproliferative neoplasms (MPNs) including those harboring the JAK2V617F mutation. ruxolitinib 0-11 Janus kinase 2 Mus musculus 43-47 29515770-6 2018 We demonstrated that ruxolitinib significantly inhibited STAT signaling in both HL and PMBL with constitutively active JAK2 signaling. ruxolitinib 21-32 Janus kinase 2 Mus musculus 119-123 29971909-1 2018 Allogeneic stem cell transplantation is currently the only curative therapy for primary myelofibrosis (MF), while the JAK2 inhibitor, ruxolitinib. ruxolitinib 134-145 Janus kinase 2 Mus musculus 118-122 29643232-5 2018 Inhibition of JAK-STAT signaling with the clinically available JAK2 inhibitor ruxolitinib abrogated NET formation and reduced thrombosis in a deep vein stenosis murine model. ruxolitinib 78-89 Janus kinase 2 Mus musculus 63-67 29042365-6 2017 Moreover, the combination of BMN673, ruxolitinib, and hydroxyurea was highly effective in vivo against JAK2(V617F)+ murine MPN-like disease and also against JAK2(V617F)+, CALR(del52)+, and MPL(W515L)+ primary MPN xenografts. ruxolitinib 37-48 Janus kinase 2 Mus musculus 103-107 29042365-6 2017 Moreover, the combination of BMN673, ruxolitinib, and hydroxyurea was highly effective in vivo against JAK2(V617F)+ murine MPN-like disease and also against JAK2(V617F)+, CALR(del52)+, and MPL(W515L)+ primary MPN xenografts. ruxolitinib 37-48 Janus kinase 2 Mus musculus 157-161 28687621-6 2017 In a mouse model of orthotopically implanted neuroblastoma cells, inhibition of JAK2/STAT3 and MEK/ERK/1/2 by ruxolitinib and trametinib potentiated tumor response to etoposide and increased overall survival. ruxolitinib 110-121 Janus kinase 2 Mus musculus 80-84 28854975-8 2017 Combination treatment with a selective JAK1/JAK2 inhibitor (ruxolitinib) and nilotinib more effectively eliminated LPCs than either therapy alone or both in vitro and in humanized Ph+ALL mice by reducing phospho-CrKL and phospho-JAK2 activities at the molecular level. ruxolitinib 60-71 Janus kinase 2 Mus musculus 229-233 25977345-4 2015 EXPERIMENTAL DESIGN: We examined the effect of JAK1/JAK2 modulation by ruxolitinib in a mouse model of fully MHC mismatched bone marrow transplant comprising in vivo tumor inoculation. ruxolitinib 71-82 Janus kinase 2 Mus musculus 52-56 26446793-10 2015 Moreover, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expressing JAK3(L857P). ruxolitinib 10-21 Janus kinase 2 Mus musculus 60-64 28339658-5 2017 This activity could be completely blocked by the broad specificity tyrosine kinase inhibitor genistein at either stage, but only at the two-cell stage was there a substantial component of activity that was sensitive to low concentrations of the JAK2-selective inhibitors TG101348 or ruxolitinib. ruxolitinib 283-294 Janus kinase 2 Mus musculus 245-249 25977345-5 2015 RESULTS: JAK1/JAK2 inhibition by ruxolitinib improved both overall survival (P = 0.03) and acute GVHD pathologic score at target organs (P <= 0.001) of treated mice. ruxolitinib 33-44 Janus kinase 2 Mus musculus 14-18 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 108-118 Janus kinase 2 Mus musculus 58-62 25549138-6 2014 Using Ruxolitinib and JAK2 as a drug target pair, here we describe in vitro screening methods that utilizes the mouse BAF3 cells expressing the random mutation library of JAK2 kinase. ruxolitinib 6-17 Janus kinase 2 Mus musculus 171-175 25721043-1 2015 In this issue of Blood, Appelmann et al provide evidence for prolonged survival and prevention of resistance in a mouse model of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) by combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, respectively. ruxolitinib 292-303 Janus kinase 2 Mus musculus 251-265 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 108-118 Janus kinase 2 Mus musculus 92-96 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 120-131 Janus kinase 2 Mus musculus 58-62 25289677-4 2014 While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNgammaR-/- T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. ruxolitinib 120-131 Janus kinase 2 Mus musculus 92-96 25289677-6 2014 In addition, prolonged administration of INCB018424 further improves survival after allo-HSCT and is superior to other JAK1/JAK2 inhibitors, such as TG101348 or AZD1480. ruxolitinib 41-51 Janus kinase 2 Mus musculus 124-128 24957147-0 2014 JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. ruxolitinib 40-51 Janus kinase 2 Mus musculus 0-4 24957147-3 2014 We investigated the role of this pathway using the JAK2 inhibitor, ruxolitinib (RUX). ruxolitinib 67-78 Janus kinase 2 Mus musculus 51-55 24957147-3 2014 We investigated the role of this pathway using the JAK2 inhibitor, ruxolitinib (RUX). ruxolitinib 80-83 Janus kinase 2 Mus musculus 51-55 24957147-4 2014 We demonstrated that the combination of RUX, at clinically achievable concentrations, with the specific and potent tyrosine kinase inhibitor nilotinib, reduced the activity of the JAK2/STAT5 pathway in vitro relative to either single agent alone. ruxolitinib 40-43 Janus kinase 2 Mus musculus 180-184 33589712-1 2021 Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. ruxolitinib 0-11 Janus kinase 2 Mus musculus 51-55 21926964-3 2012 We performed a high-throughput in vitro screen to identify point mutations in JAK2V617F that would be predicted to have potential clinical relevance and associated with drug resistance to the JAK2 inhibitor ruxolitinib (INCB018424). ruxolitinib 207-218 Janus kinase 2 Mus musculus 78-82 21926964-3 2012 We performed a high-throughput in vitro screen to identify point mutations in JAK2V617F that would be predicted to have potential clinical relevance and associated with drug resistance to the JAK2 inhibitor ruxolitinib (INCB018424). ruxolitinib 220-230 Janus kinase 2 Mus musculus 78-82 24251790-6 2013 The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F. ruxolitinib 56-67 Janus kinase 2 Mus musculus 9-13 24251790-6 2013 The best JAK2/JAK1 and PI3K inhibitor combination pair (ruxolitinib and GDC0941) reduces spleen weight in nude mice inoculated with Ba/F3 cells expressing TpoR and JAK2 V617F. ruxolitinib 56-67 Janus kinase 2 Mus musculus 164-168 22875628-3 2013 Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) > 10 muM for all). ruxolitinib 0-11 Janus kinase 2 Mus musculus 72-76 34808021-6 2022 Both ruxolitinib and obatoclax significantly reduced spleen weights in a murine Jak2V617F MPN model but did not show additive effect. ruxolitinib 5-16 Janus kinase 2 Mus musculus 80-84 34145036-2 2021 The JAK2 inhibitors Ruxolitinib and Fedratinib have been approved for treatment of MF, but they do not offer significant improvement of bone marrow fibrosis. ruxolitinib 20-31 Janus kinase 2 Mus musculus 4-8 34741118-2 2022 The JAK inhibitor Ruxolitinib can reduce constitutional symptoms but it does not substantially improve bone marrow fibrosis. ruxolitinib 18-29 Janus kinase 2 Mus musculus 4-7 34480104-7 2021 Combined pharmacologic JAK2/ERK1/2 inhibition with ruxolitinib and ERK inhibitors reduced proliferation of Jak2V617F cells and corrected erythrocytosis and splenomegaly of Jak2V617F MPN mice. ruxolitinib 51-62 Janus kinase 2 Mus musculus 107-111 34480104-7 2021 Combined pharmacologic JAK2/ERK1/2 inhibition with ruxolitinib and ERK inhibitors reduced proliferation of Jak2V617F cells and corrected erythrocytosis and splenomegaly of Jak2V617F MPN mice. ruxolitinib 51-62 Janus kinase 2 Mus musculus 172-176 34184542-0 2021 Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models. ruxolitinib 0-11 Janus kinase 2 Mus musculus 20-24 33542546-2 2021 MPN treatment options currently mainly consist of cytoreductive therapy with hydroxyurea and JAK2 inhibitors such as ruxolitinib and fedratinib. ruxolitinib 117-128 Janus kinase 2 Mus musculus 93-97 34440089-0 2021 Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. ruxolitinib 0-11 Janus kinase 2 Mus musculus 80-84 34440089-10 2021 Collectively, our studies suggest that ruxolitinib might suppress the ALDH1A3 activation through the JAK2/STAT1/3 pathway in cholangiocarcinoma, and trials should be undertaken to evaluate its efficacy in clinical therapy. ruxolitinib 39-50 Janus kinase 2 Mus musculus 101-105 34196308-5 2021 Inhibition of the IFN response pathway using the JAK1/JAK2 inhibitor ruxolitinib decreased PD-L1 expression on myeloid-derived suppressor cells in the brain and further potentiated the therapeutic effect of MV-s-NAP-uPA and anti-PD1. ruxolitinib 69-80 Janus kinase 2 Mus musculus 54-58 35352806-6 2022 Jak2 is activated in Nras mutant HSC and progenitors (HSPCs) and inhibiting Jak2 with Ruxolitinib significantly decreases Stat5 activation and HSPC hyper-proliferation in vivo in NrasG12D mice. ruxolitinib 86-97 Janus kinase 2 Mus musculus 0-4 35352806-6 2022 Jak2 is activated in Nras mutant HSC and progenitors (HSPCs) and inhibiting Jak2 with Ruxolitinib significantly decreases Stat5 activation and HSPC hyper-proliferation in vivo in NrasG12D mice. ruxolitinib 86-97 Janus kinase 2 Mus musculus 76-80 35278531-6 2022 The erythropoietin receptor activates Janus kinase 2 (Jak2) and we found treatment of Fancc-/- mice with ruxolitinib (Jak1/2-inhibitor) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes. ruxolitinib 105-116 Janus kinase 2 Mus musculus 38-52 35278531-6 2022 The erythropoietin receptor activates Janus kinase 2 (Jak2) and we found treatment of Fancc-/- mice with ruxolitinib (Jak1/2-inhibitor) decreased anemia, enhanced granulocytosis, delayed clonal progression and prolonged survival during repeated emergency granulopoiesis episodes. ruxolitinib 105-116 Janus kinase 2 Mus musculus 54-58 35169231-6 2022 Pharmacologic JAK2 inhibition with ruxolitinib also leads to defects in cholesterol efflux and accelerates atherosclerosis. ruxolitinib 35-46 Janus kinase 2 Mus musculus 14-18 35020848-4 2022 JAK2 inhibition by ruxolitinib mimicked loss of TSLPR function in vivo and further decreased TSLP expression in the EAE mouse brain. ruxolitinib 19-30 Janus kinase 2 Mus musculus 0-4 35020848-6 2022 In vitro experiments using BV-2murine microglia revealed that TSLP directly induced NLRP3 expression, phosphorylation of JAK2 but not JAK1orJAK3, and IL-1beta release, which were markedly inhibited by ruxolitinib. ruxolitinib 201-212 Janus kinase 2 Mus musculus 121-125 34367186-2 2021 Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway. ruxolitinib 0-11 Janus kinase 2 Mus musculus 94-98 34367186-2 2021 Ruxolitinib (Rux), a selective oral JAK 1/2 inhibitor, reduces inflammatory responses via the JAK2/STAT3 pathway. ruxolitinib 13-16 Janus kinase 2 Mus musculus 94-98 34367186-14 2021 Furthermore, Rux administration inhibited the expression of proinflammatory cytokines, including TNF-alpha, IFN-gamma, HMGB1, IL-1beta, IL-2, and IL-6, suggesting that Rux may alleviate IS injury by inhibiting proinflammatory reactions via JAK2/STAT3 signaling pathway regulation. ruxolitinib 13-16 Janus kinase 2 Mus musculus 240-244 34367186-17 2021 Rux application suppressed lipopolysaccharide (LPS)-induced NLRP3 inflammasome secretion and JAK2/STAT3 pathway activation in the OGD/R model in vitro. ruxolitinib 0-3 Janus kinase 2 Mus musculus 93-97 32818511-0 2020 Ruxolitinib attenuates intimal hyperplasia via inhibiting JAK2/STAT3 signaling pathway activation induced by PDGF-BB in vascular smooth muscle cells. ruxolitinib 0-11 Janus kinase 2 Mus musculus 58-62 33567809-12 2021 Ruxolitinib decreased the abdominal aorta diameter and the incidence of abdominal AA in the JAK2V617F-BMT mice. ruxolitinib 0-11 Janus kinase 2 Mus musculus 92-96 32818511-3 2020 Ruxolitinib, a potent Janus kinase (JAK) 1 and 2 inhibitor, has been reported to significantly block the proliferation-related signaling pathway of JAK2/signal transducers and activators of transcription 3 (STAT3) and harbor a broad spectrum of anti-cancer activities, including proliferation inhibition, apoptosis induction, and anti-inflammation. ruxolitinib 0-11 Janus kinase 2 Mus musculus 148-152 32818511-10 2020 The JAK2/STAT3 signaling pathway involved in the effects of ruxolitinib on VSMCs was detected by western blotting with the specific pathway inhibitor AG490. ruxolitinib 60-71 Janus kinase 2 Mus musculus 4-8 32818511-13 2020 In addition, ruxolitinib inhibited the PDGF-BB-induced activation of the JAK2/STAT3 signaling pathway and decreased the expression of proliferation related-proteins cyclinD1 and PCNA in VSMCs (p < 0.05). ruxolitinib 13-24 Janus kinase 2 Mus musculus 73-77 32818511-14 2020 CONCLUSION: Our findings suggest that ruxolitinib inhibits VSMC proliferation in vivo and in vitro by suppressing the activation of the JAK2/STAT3 signaling pathway. ruxolitinib 38-49 Janus kinase 2 Mus musculus 136-140 32562787-10 2020 Based on these in vitro results, we also explored the effects of JAK2/1 inhibition by ruxolitinib in vivo, on mouse macrophages in a model of HOCl-induced ILD, that mimics scleroderma-associated ILD. ruxolitinib 86-97 Janus kinase 2 Mus musculus 65-71 32929154-5 2020 Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. ruxolitinib 60-71 Janus kinase 2 Mus musculus 43-47 31195136-4 2019 This effect was blocked by ruxolitinib, a JAK1/JAK2 inhibitor. ruxolitinib 27-38 Janus kinase 2 Mus musculus 47-51 31732720-0 2020 Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. ruxolitinib 20-31 Janus kinase 2 Mus musculus 63-67